IL67313A0 - Pharmaceutical compositions comprising neurotropic factors for treating amyotrophic lateral sclerosis,parkinson disease and alzheimer disease and methods for diagnosing these diseases - Google Patents

Pharmaceutical compositions comprising neurotropic factors for treating amyotrophic lateral sclerosis,parkinson disease and alzheimer disease and methods for diagnosing these diseases

Info

Publication number
IL67313A0
IL67313A0 IL67313A IL6731382A IL67313A0 IL 67313 A0 IL67313 A0 IL 67313A0 IL 67313 A IL67313 A IL 67313A IL 6731382 A IL6731382 A IL 6731382A IL 67313 A0 IL67313 A0 IL 67313A0
Authority
IL
Israel
Prior art keywords
disease
specific
hormones
neurotrophic
als
Prior art date
Application number
IL67313A
Other languages
English (en)
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of IL67313A0 publication Critical patent/IL67313A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL67313A 1981-12-22 1982-11-19 Pharmaceutical compositions comprising neurotropic factors for treating amyotrophic lateral sclerosis,parkinson disease and alzheimer disease and methods for diagnosing these diseases IL67313A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8138627 1981-12-22

Publications (1)

Publication Number Publication Date
IL67313A0 true IL67313A0 (en) 1983-03-31

Family

ID=10526778

Family Applications (1)

Application Number Title Priority Date Filing Date
IL67313A IL67313A0 (en) 1981-12-22 1982-11-19 Pharmaceutical compositions comprising neurotropic factors for treating amyotrophic lateral sclerosis,parkinson disease and alzheimer disease and methods for diagnosing these diseases

Country Status (10)

Country Link
EP (1) EP0082612B1 (de)
JP (1) JPS58154514A (de)
AT (1) ATE22658T1 (de)
CA (1) CA1223513A (de)
DE (1) DE3273612D1 (de)
DK (1) DK560682A (de)
ES (1) ES518386A0 (de)
FI (1) FI824276L (de)
IL (1) IL67313A0 (de)
ZA (1) ZA828932B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017375A (en) * 1982-11-24 1991-05-21 Baylor College Of Medicine Method to prepare a neurotrophic composition
EP0258111A3 (de) * 1986-08-07 1989-01-25 FIDIA S.p.A. Neuronotrophischer Faktor
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
FR2657784A1 (fr) * 1990-02-05 1991-08-09 Pasteur Institut Facteur endogene cerebral, procede d'obtention et applications therapeutiques et diagnostiques.
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US20060153797A1 (en) * 2004-06-11 2006-07-13 Bortolotto Susan K Tissue material and matrix

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE639638C (de) *
DE560325C (de) * 1929-06-08 1932-10-01 Schering Kahlbaum Ag Verfahren zur Herstellung eines die zentralen Taetigkeiten foerdernden und regulierenden Reizstoffes aus waessrigen Auszuegen von Wirbeltierhirn oder dessen Zubereitungen
DE1095464B (de) * 1956-05-22 1960-12-22 Univ Tulane Verfahren zur Herstellung eines Heilmittels zur Behandlung von Schizophrenie und anderen Geisteskrankheiten
US3989819A (en) * 1969-03-05 1976-11-02 American Cyanamid Company Process for separating proteins from central nervous system tissue and treating experimentally induced demyelinating diseases

Also Published As

Publication number Publication date
ES8406499A1 (es) 1984-08-01
JPS58154514A (ja) 1983-09-14
ZA828932B (en) 1984-03-28
FI824276A0 (fi) 1982-12-13
DK560682A (da) 1983-06-23
EP0082612B1 (de) 1986-10-08
EP0082612A1 (de) 1983-06-29
ES518386A0 (es) 1984-08-01
FI824276A7 (fi) 1983-06-23
FI824276L (fi) 1983-06-23
DE3273612D1 (en) 1986-11-13
CA1223513A (en) 1987-06-30
ATE22658T1 (de) 1986-10-15

Similar Documents

Publication Publication Date Title
German et al. Disease‐specific patterns of locus coeruleus cell loss
Davis et al. Stress-induced activation of prefrontal cortex dopamine turnover: blockade by lesions of the amygdala
Chu et al. Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia
Messer Jr et al. Evidence for a preferential involvement of M1 muscarinic receptors in representational memory
KR920701432A (ko) 뇌유도성 향신경성 인자
NL300140I2 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
DE68912419D1 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
IL67313A0 (en) Pharmaceutical compositions comprising neurotropic factors for treating amyotrophic lateral sclerosis,parkinson disease and alzheimer disease and methods for diagnosing these diseases
Klapdor et al. Facilitation of learning in adult and aged rats following bilateral lesions of the tuberomammillary nucleus region
Barg et al. Opioid receptor density changes in Alzheimer amygdala and putamen
Lowenthal et al. a-Albumin (glial fibrillary acidic protein) in normal and pathological human brain and cerebrospinal fluid
Spahn et al. Percentage of projection neurons and various types of interneurons in the human claustrum
Pakaslahti On the diagnosis of schizophrenic psychoses in clinical practice.
Singh et al. Effect of intrahippocampal injection of atropine on different phases of a learning experiment
DE58901872D1 (de) Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
Consolo et al. The cerebrospinal fluid choline levels in patients with Huntington's chorea: Negative effect of haloperidol treatment
Linton et al. Personality type and symptom formation.
Garifullin et al. GLIAL CELLS AND THE NEUROGENESIS
PARDES et al. Dr. Pardes and Associates Reply
Mendlewicz Genetics and Psychiatry
Falkai et al. Qualitative and quantitative assessment of pre-alpha-cell clusters in the entorhinal cortex of schizophrenics. A neurodevelopmental model of schizophrenia?
Fujita et al. ANALYSIS OF DOPAMINE TRANSPORTER-EXPRESSING NEURON-SPECIFIC TYROSINE HYDROXYLASE KNOCKOUT MICE.
Domino et al. Diagnosis of depression in alcoholics.
Klug Hypnosis as a treatment modality in psychiatric practice.